Acute Renal Failure Clinical Trial
Official title:
Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization
Hypothesis:
Cystatin C compared with creatinine is a better and earlier marker of contrast-induced
nephropathy in high and intermedium risk cardiac catheterization patients.
Primary Objective:
Establish if Cystatin C is superior detecting contrast-induced nephropathy than creatinine
in high and intermedium risk cardiac catheterization patients.
Contrast induced-nephropathy is a complication that is underestimated in clinical practice
after cardiac catheterization. During the last 30 years, because of the increasing use of
contrast medium for diagnostic and therapeutic procedures, this has become the third
in-hospital cause of acute renal failure (12%). That's why, it is necessary to establish an
earlier marker of renal dysfunction that can help us in the diagnosis and allow us to
initiate the appropriate therapeutics, because depending on the severity of the renal
damage, it can increase the cardiovascular risk and morbidity.
The risk of contrast medium nephropathy is still present even with the use of low osmolarity
contrast media, and many patients increase their in-hospital days, costs and hemodialysis
requirement.
Cystatin C is a non glucosylated protein produced in nucleated cells in a constant rate, and
because of its low molecular weight it's filtered through the glomerular membrane without
restriction and it's fully reabsorbed in the proximal tubule, that's why it's considered an
excellent marker evaluating the glomerular filtration rate in patients with acute renal
failure during the first 24-48 hours.
We propose that Cystatin C can be useful as an earlier and superior marker of
contrast-induced nephropathy in high and intermedium cardiac catheterization patients.
;
Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01946113 -
Mineral-Homeostasis in Continuous Renal Replacement Therapy
|
N/A | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Withdrawn |
NCT00993733 -
Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care
|
N/A | |
| Terminated |
NCT00978354 -
Furosemide in Early Acute Kidney Injury
|
Phase 2/Phase 3 | |
| Completed |
NCT00120263 -
Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma
|
N/A | |
| Completed |
NCT04799600 -
The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
|
||
| Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
| Completed |
NCT02858531 -
Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
|
||
| Recruiting |
NCT05282732 -
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
|
||
| Completed |
NCT01467466 -
Prevention of Serious Adverse Events Following Angiography
|
Phase 3 | |
| Completed |
NCT01979042 -
Urinary Markers for Unilateral Kidney Obstruction
|
N/A | |
| Completed |
NCT01280617 -
Low Dose Thymoglobin in Renal Transplant Patients
|
N/A | |
| Completed |
NCT00780351 -
Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f)
|
N/A | |
| Completed |
NCT00971971 -
Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients
|
N/A | |
| Completed |
NCT00076219 -
Acute Renal Failure Trial Network (ATN) Study
|
Phase 3 | |
| Recruiting |
NCT04599569 -
Influence of Renal Replacement TherApy on Indirect Calorimetry
|
||
| Completed |
NCT03727204 -
Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
|
||
| Completed |
NCT06005896 -
A Clinical Model for Dialysis Discontinuation in AKI
|
||
| Completed |
NCT03004950 -
Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
|
||
| Completed |
NCT03627884 -
Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
|
Phase 4 |